Biolargo, Inc. news
BioLargo, Inc. (OTCQB: BLGO) subsidiary Clyra Medical Technologies, Inc. has successfully concluded a financing from Sanatio Capital LLC for $750,000 in equity and a forward commitment to provide a $5,000,000 operating line of credit, to support the FDA approval and commercial launch of Clyra`s advanced wound care products.
BioLargo, Inc. (OTCQB: BLGO) announced today the United States Patent and Trademark Office issued patent 8,846,067 titled “antimicrobial solutions and methods” which covers the use of BioLargo’s iodine technology in its platform of liquid and hydrogel solutions. The liquid and gel technologies are foundational to multipl
BioLargo, Inc. (OTCQB: BLGO) will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at the New York Palace Hotel. Dennis Calvert, BioLargo`s president, is scheduled to present at 2:55 p.m. ET.
A webcast of the live presentation will be available at www.BioLargo.com where it will be retained for 90 days. A copy of the slides management will be presenting will also be available on the company`s we
BioLargo, Inc.`s president and CEO Dennis Calvert was recently interviewed by SNN Live at two investor conferences. Mr. Calvert introduces BioLargo and discusses the company`s progress in commercializing its advanced iodine platform technology. Video of both interviews can be accessed by clicking on the following links.
- Marcum`s 3rd Annual MicroCap Conference in New York City on May 29th. https://www.youtube.com/watch?v=_4Ts
- Opens recurring sales channels for health care related products -
- Establishes working capital line of credit to support sales efforts -
BioLargo, Inc. (OTCQB: BLGO) announced its subsidiary Odor-No-More, Inc. was assigned National Stock Numbers (NSNs) for multiple products by the Defense Logistics Information Service (DLIS), allowing the U.S. military, and federal and civil agencies, to order these products as a stock item directly from the company. The NSNs w